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Abstract
Background: We previously showed that microglia damage blood brain barrier (BBB) components following
ischemic brain insults, but the underlying mechanism(s) is/are not well known. Recent work has established the
contribution of toll-like receptor 4 (TLR4) activation to several brain pathologies including ischemia,
neurodegeneration and sepsis. The present study established the requirement of microglia for lipopolysaccharide
(LPS) mediated endothelial cell death, and explored pathways involved in this toxicity. LPS is a classic TLR4 agonist,
and is used here to model aspects of brain conditions where TLR4 stimulation occurs.
Methods/Results: In monocultures, LPS induced death in microglia, but not brain derived endothelial cells (EC).
However, LPS increased EC death when cocultured with microglia. LPS led to nitric oxide (NO) and inducible NO
synthase (iNOS) induction in microglia, but not in EC. Inhibiting microglial activation by blocking iNOS and other
generators of NO or blocking reactive oxygen species (ROS) also prevented injury in these cocultures. To assess the
signaling pathway(s) involved, inhibitors of several downstream TLR-4 activated pathways were studied. Inhibitors
of NF-B, JAK-STAT and JNK/SAPK decreased microglial activation and prevented cell death, although the effect of
blocking JNK/SAPK was rather modest. Inhibitors of PI3K, ERK, and p38 MAPK had no effect.
Conclusions: We show that LPS-activated microglia promote BBB disruption through injury to endothelial cells, and
the specific blockade of JAK-STAT, NF-B may prove to be especially useful anti-inflammatory strategies to confer
cerebrovascular protection.
Background
M i c r o g l i aa r et h eb r a i n ’s resident immune cell, and are
among the first to respond to brain injury. Microglia are
rapidly activated and migrate to the affected sites of neu-
ronal damage where they secrete both cytoxic and cyto-
trophic immune mediators [1]. Homeostasis of the
brain’s microenvironment is maintained by the blood-
brain barrier (BBB), formed by endothelial cell tight junc-
tions. The BBB is now recognized to comprise complex
and dynamic cellular systems, whereby astrocytes, micro-
glia, perivascular macrophages, pericytes and the basal
membrane interact with endothelial cells tight junctions,
and serve as a controlled functional gate to the brain [2].
Endothelial cell permeability, activation and injury play a
critical role in the progression of disease processes
including inflammation, atherosclerosis, and tumor
angiogenesis [3]. Microglia are assumed to play a crucial
role in the formation and homeostasis of the BBB [4]. In
response to potential pathogen invasion, microglia react
t od e s t r o yi n f e c t i o u sa g e n t sb e f o r et h e yd a m a g et h e
neural tissue. Moreover, microglial activation is crucial in
the progression of multiple inflammatory diseases via the
release of inflammatory mediators such as cytokines, NO,
and prostaglandins [1,5].
We previously showed that microglia potentiated injury
to BBB components following ischemia like insults, and
pharmacological inhibition of microglia reduced BBB dis-
ruption in an experimental model of stroke [6]. Here we
expand on these findings to identify underlying mechan-
isms of this microglial toxicity. Since many insults are
capable of damaging endothelial cells in the absence of
microglia, we focused on a model of endothelial cell
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better understand their role in potentiating injury.
Methods
Chemicals and reagents
All reagents were high grade and were purchased from
Sigma with the following exceptions. RPMI, DMEM, Cal-
cein and ethidium homodimer and other culture reagents
were purchased from Invitrogen Inc (Grand Island, NY,
USA) and the UCSF cell culture facility (UCSF, San
Francisco, CA). Fetal bovine Serum Defined (FBS) was pur-
chased from Hyclone Laboratories (Logan, UT, USA).
PD98059, a MEK inhibitor; SP600 125, a JNK inhibitor;
wortmanin an inhibitor of PI3 kinase and pyrrolidinecarbo-
dithoic acid (PDTC), a NF-B inhibitor); AG490, a JAK2-
STAT inhibitor were purchased from Calbiochem (San
Diego, CA). LPS (Escherichia coli, O26:B6), aminoguandine,
apocynin, allopurinol, minocycline, N(omega)-hydroxy-L-
arginine (NOHA), indomethacin and amino-3-morpholi-
nyl-1,2,3-oxadiazolium chloride (SIN-1) were purchased
from Sigma (St Louis, MO). Drugs were dissolved in
DMSO or ethanol and stored at -20°C and either used
(final concentration of vehicle 0.1% (v/v or dried down and
resuspended in PBS/0.1% bovine serum albumin (BSA).
Mitogen activated kinase (MAPK) Anti-phospho-ERK
monoclonal antibody (mAb), anti-ERK polyclonal antibody
(#4370), anti-phospho-p38 MAPK mAb (# 4631), anti-
phospho-JNK/SAPK mAb (#4668) were from Cell Signaling
T e c h n o l o g y( D a n v e r s ,M A ) ;a n t i - N F - Bp65 (# SC-8008),
anti-IBa (# SC-1643) and respective horseradish peroxi-
dase-coupled secondary antibodies were purchased from
Santa Cruz (Santa Cruz, CA) and. Antibodies against iNOS
( # 61043), iNOS positive control lysates (#611473) were
from BD Biosciences (BD Biosciences, Lexington, KY).
Cell culture
BV2 cells
The immortalized mouse microglia cell line, BV2, ori-
ginally generated by Blasi and colleagues [7], were
obtained from Dr. Theo Palmer. These cells were
exhaustively shown to exhibit many phenotypic and
functional properties of reactive microglia cells and are
suitable model of inflammation [8]. Cells were grown
and maintained in RPMI supplemented with 10% fetal
bovine serum and antibiotics (penicillin/streptomycin,
100U/ml). Under a humidified 5% CO2/95% air atmo-
sphere and at 37°C, cells were plated in 75 cm
2 cell cul-
ture flask (Corning, Acton, MA, USA) and were split
twice a week. For the experiments, cells were plated on
6-well dishes (1-2 × 10
6cells/well).
bEND.3 cells
The immortalized mouse brain microvascular endothe-
lial cell line, bEND.3, was purchased from American
Type Culture Collection (Manassas, VA, USA). These
cells were derived from mouse brain endothelial cells
prepared from cerebral capillaries of C57BL/6 mice [9].
Cells were grown in Dulbecco’s modified Eagle’sm e d -
ium (DMEM) supplemented with 450 mg/dl glucose,
10% fetal bovine defined, and antibiotics.
Cocultures of BV2 and bEND.3 cells were generated
by growing bEND.3 cells to confluence in DMEM with
serum. BV2 cells were then seeded on the top of the
monolayer with the bEND.3 cells and allowed to adhere
for 24 hours before each experimental design. A ratio of
1:10 (BV2: bEND.3 cells) was used to model the relative
proportions observed in vivo.
Each cell type described above were characterized by
morphological appearance, viability with trypan blue or
calcein, immunocytochemical staining or Western blot-
ting using antibodies that recognizes specific markers
(VW Factor, PECAM-1 and claudin-5 for bEND.3; IBA
lectin for BV2 cells as previously described [6,10,11].
Experimental protocols
Cell treatment
Cells were cultured to approximately 80% confluence,
and fresh serum-free media was added for 4-24 h before
LPS or inhibitors treatments. All inhibitors were applied
1 h before experimental treatment. Of note, we did preli-
minary dose finding and toxicity studies for all the selec-
tive inhibitors used. We selected optimal concentrations
that both inhibited NO generation without cytotoxic
effect on cells as indicated for each drug accordingly.
Fluorescence microscopy
Fluorescence immunocytochemistry was performed on
cells as previously described [12]. After washing, cells were
fixed with acetone/methanol (1:1) 5 min at -20°C. Alterna-
tively, cells were fixed in 4% paraformaldehyde for 30 min
at room temperature. The cells were then washed twice
with PBS containing 0.2% Triton X-100 for 15 min. Non-
specific binding sites were blocked in blocking buffer (2%
BSA and 0.2% Triton X-100 in PBS) for 2 hr. The cells
were incubated with primary antibody specific marker for
the vascular unit cells as indicated at 1:100 dilution in
blocking buffer overnight at 4°C and then washed three
times with blocking buffer, 10 min per wash. The cells
were incubated with FITC- or Texas Red-conjugated sec-
ondary antibodies (Jackson ImmunoResearch, West
Grove, PA) at 1:100 dilution in blocking buffer at RT for
1 h, then washed 2 times in blocking buffer, and one time
in PBS, 10 min per wash. Fluorescence was visualized with
an epifluorescence microscope (Zeiss Axiovert; Carl Zeiss
Inc), and images were obtained on a PC computer using
Axiomatic software (Zeiss Inc).
NO measurement
LPS or vehicle was then added as described above, and
cells were returned to the incubator. After incubation
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and either stored at -80°C or used immediately for
nitrite content analysis. Accumulation of NO in cultures
media was determined by the Greiss reagent using
nitrite as standard as previously described [13-15].
Immunoblotting
After each treatment period, cells plated on 6 well or
60-mm dishes were washed with cold phosphate buf-
fered saline, and scraped into 500 μl lysis buffer consist-
ing of 20 mM Tris, pH7.5, 150 mM NaCl, 1% Triton
X-100, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl-
fluoride (PMSF), 50 mM NaF, and 5 mg/ml aprotinin.
Lysates were sonicated and centrifuged at 10,000 × g for
5 min. The supernatant was collected and either used
immediately or frozen at -80°C. Protein concentration
was determined using the BCA protein assay (Pierce,
Rockford, IL), and equal amounts of protein were loaded
per lane onto 10-12% sodium dodecylsulfate-polyacryla-
mide gels, and were electrophoresed (SDS-PAGE) as
previously described [12,16]. Gels were then transferred
onto enhanced chemiluminescence (ECL)-nylon mem-
branes in transfer buffer containing 48 mM Tris,
150 mM glycine, and 10% methanol using a Transblot
apparatus (Biorad, Hercules, CA, USA) at 100 V for
1 hr at 4°C. The membranes were saturated in 10 mM
Tris, pH7.4, 150 mM NaCl, and 0.1% Tween-20, and 5%
non-fat dry milk for 1 hr at room temperature and then
probed with specific polyclonal antisera for iNOS the
same buffer for 1 h at room temperature with
gentle agitation. anti-phospho-p38 MAPK mAb, anti-
phospho-JNK mAb, and anti-phospho JAK2 rabbit poly-
clonal antibodies were from Cell Signaling Technology
(Danvers, MA). For all antibodies used working dilution
was (1:500 and 1;1000) for rabbit and mouse primary
antibodies respectively. Membranes were washed three
times with 10 mM Tris, 150 mM NaCl, and 0.1%
Tween-20. Bound antibodies were identified after incu-
bation with peroxidase-conjugated anti-rabbit antibodies
(1:2000 dilution in saturation buffer) for 1 h at room
temperature. Membranes were then rewashed three
times and the position of the individual proteins was
detected by chemiluminescence ECL according to the
manufacturer’s instruction
Assessment of IB-a degradation and NF-B nuclear
translocation
Cytoplasmic and nuclear extracts were prepared as pre-
viously described [17]. IBa in cytoplasmic extracts and
NF-B subunit p65 in nuclear extracts were detected by
Western blot using specific antibodies anti-NF-Bp65
and anti-IBa [18]. We also assessed NF-Ba c t i v a t i o n
using anti- phospho NF-B p65 subunit antibody (rabbit
polyclonal, Cell Signaling Technology) by western blot.
Cell viability assays
MTT was used to assay cell viability. Trypan blue exclu-
sion and calcein/ethidium homodimer dual stain were
also used to morphologically assay for cell viability
(Live/dead, calcein/ethidium homodimer dual stain) as
previously described [12,14]. Estimates of relative
bEND.3 and BV2 cell viability were made from manual
counts from cultures labelled with calcein and appropri-
ate cell type markers, and manual counts were made
from 5 non-overlapping fields.
Statistical analysis
Data are presented as mean ± SEM. Significant differ-
ences were determined by either Student’s two-tailed
t-test for comparison of the means of two samples or
analysis of variance (ANOVA) for the comparison of
more than two sample means followed by Newman-
Keuls post-hoc testing for multiple comparisons among
sample means. The significance level was set at P< 0.05.
Results
LPS dose response and NO generation
We investigated the effects of a proinflammatory stimu-
lus on BV2 cells. Our first observation showed that LPS
induced injury to BV2 cells as detected by analysis of
cell morphology and viability assays (Figure 1A-G). We
also found that LPS (0.01-1 μg/ml) induced NO produc-
tion (Figure 1H), which was dose dependent and inver-
sely related to cell viability. LPS also induced iNOS
protein in a dose dependent manner (Figure 1I). LPS
also increased the levels of ROS generation and other
proinflammatory markers COX-2 and TNFa (not
shown). Thus, all subsequent experiments used a LPS
concentration of 1 μg/ml.
LPS does not affect endothelial cell viability or NO/iNOS
induction
In contrast, LPS (1 μg/ml) had no direct effect on
bEND.3 cell viability, and did not increase NO or induce
iNOS (Figure 2). The baseline levels of NO present in
the media of bEND.3 cells were likely generated by
eNOS, which is known to be constitutively expressed in
these cells.
NO donors affect BV2 cells in a manner similar to LPS
Because LPS stimulated NO generation in BV2 cells,
we explored whether a NO donor behaved in a similar
fashion. Accordingly, BV2 cells were treated with serial
doses of the NO donor SIN-1 for 24 h. Like LPS, SIN-
1 (0.1-1 mM) dose dependently increased NO genera-
tion and reduced BV2 cell viability (Figure 3). While
SIN-1 did not alter cell viability at the lowest doses
studied, NO accumulation was more dramatically
affected.
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Figure 1 LPS induces BV2 cell death. Compared to control BV2 cells (A, C, E), LPS exposure for 24 hours led to increased cell death in a dose
dependent manner (B, D, F, G). Fewer numbers of BV2 cells (B) are observed after LPS (1 μg/mL) treatment compared to those given vehicle (A)
(trypan blue stain). Calcein stained cells reveal viable cells in green (C, D). Double staining with calcein (live cells in green) and ethidium
homodimer (nuclear stain of dead cells in red) (E, F). LPS induces generation of iNOS and NO in a dose dependent manner in microglia.
BV2 cells were incubated in vehicle (CTL) or LPS for 24 h. Thereafter, cells were harvested, and lysates were used for Western blot. Nitrite levels, a
measure of NO generation, was determined from supernatants. LPS reduced BV2 cell viability (G, n = independent observations) and increased NO
generation (H, n = 12 independent observations) in a dose dependent manner. iNOS protein was similarly increased with LPS concentration (I).
Shown is a representative blot. *P < 0.05 versus control.
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Page 4 of 15Differential effect of BV2 viability & NO/iNOS generation
by various immune inhibitors
In order to determine whether the increase in NO by
LPS is specific to iNOS; we tested the effect of various
immune inhibitors on BV2 cell viability and NO accu-
mulation. We found that NOS (aminoguanidine and L-
NMMA) and ROS (apocynin, allopurinol, indomethicin)
inhibitors all reduced LPS-induced cell death in BV2
cells (Figure 4A). Interestingly, aminoguanidine (AG,
a relatively selective iNOS inhibitor, 1m M )a n d
L-NMMA (a non selective NOS inhibitor, 100 μM) both
abrogated NO accumulation, as did apocynin (APO, a
NADPH oxidase inhibitor, 1m M ), allopurinol (ALLO, a
xanthine oxidase inhibitor, 50 μM) and minocycline
(MINO, 10 μM) an antibiotic known to have multiple
anti-inflammatory properties [19], but not COX-2 (indo-
methacin, 10 μM)o ra r g i n a s e( N O H A ,10 μM) inhibi-
tors (Figure 4B). Neither NOS inhibitor had an effect on
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Figure 2 LPS does not affect iNOS expression and cell survival in endothelial cells.b E N D . 3c e l l se x p o s e dt o1μg/ml LPS for 24 h fail to
experience any cell death (A, C, D-control, B, E, F-LPS treatment). Shown are trypan blue (A, B), calcein (C, E) and ethidium homodimer (D, F)
stains. LPS has no effect on bEND.3 cell viability as assessed by MTT staining (H) and NO generation (G). LPS also fails to induce iNOS protein in
bEND.3 cells (I). iNOS protein is readily induced by LPS in BV2 cells as a positive control. Data are representative of 3-5 experiments.
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Page 5 of 15Figure 3 SIN-1, a NO donor shows similar patterns on viability and NO accumulation in microglia as LPS treatment.B V 2c e l l sw e r e
incubated in increasing doses of SIN-1 for 24 hr. NO accumulation as determined by the Greiss reagent (A) increased in a dose dependent
manner. Viability, as assessed by light microscopy and MTT quantification, also decreased, but only at concentrations of 0.5 mM or greater. n = 6
independent observations, *P < 0.05 versus control.
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with these compounds’ ability to inhibit NOS activity
but not protein levels.
NF-B, JAK/STAT and JNK are involved in LPS activation
of BV2 cells
Transcription factors NF-kappa B (NF-B) and mitogen-
activated protein kinase (MAPK) are known to play
upstream roles in NO/iNOS signaling. To determine
which of these pathways is activated by LPS, BV2 cells
were treated with LPS and respective inhibitors, then col-
lected at different timepoints ranging from 5-60 min.
Western blot analysis using phospho specific antibodies
showed that LPS triggered an early (5 min) increase in the
activation of stress activated p38 MAPKs, whereas c-Jun
N-terminal kinases (JNKs/SAPKs) and JAK-STAT activa-
tion was detected at 30 min (Figure 5). LPS also induced
degradation of I-B with increases in nuclear NF-B
expression by 30 min and phosphorylated NF-kB was
observed as early as 5 min.
To further assess the functional significance of these
pathways in iNOS induction and NO accumulation by LPS,
we studied a panel of inhibitors. Pyrodinyl dithiocarbamate
(PDTC, 50 μM)t oi n h i b i tN F - B and AG490 (10 μM), a
JAK-STAT inhibitor both abrogated NO accumulation,
while the PI3K inhibitor wortmanin (100 nM), the MEK1
inhibitor PD98050 (20 μM) and the p38 MAPK inhibitor
SB203580 (10 μM) did not. However, the JNK kinase inhi-
bitor SP600125 (10 μM) only partially prevented NO accu-
mulation (Figure 6B). On the other hand, while PI3K,
MEK1 and p38 MAPK inhibition did not prevent cell
death, JAK/STAT, and JNK kinase pathway inhibition pro-
tected BV2 cells from LPS-induced injury (Figure 6A).
LPS induces endothelial cell death in the presence of
microglia. Reversal by NOS and ROS inhibition
While LPS was not directly toxic to bEND.3 cells, cocul-
tures of bEND.3 cells with BV2 cells led to LPS induced
injury to bEND.3 cells (Figure 7A-C) and NO accumula-
tion (Figure 7D). This toxic effect seemed to require
cell-cell interactions, since conditioned media from LPS
activated BV2 cells failed to induce bEND.3 cell injury
(data not shown). The proportion of cell death in these
cocultures was mostly the bEND.3 cells, as bEND.3
monolayer integrity was almost completely disrupted by
LPS, but BV2 cells seemed relatively spared (Figure 7A).
The proportion of remaining BV2 cells was about 20-
30%, but overall cell death was 70-80% (Figure 7 B-C).
Thus, LPS stimulation led to death of mostly bEND.3
cells. Pretreatment with NOS (L-NMMA and aminogua-
nidine) and ROS inhibitors (apocynin and allopurinol)
markedly prevented cell death and b.END3 monolayer
disruption in this experimental model. Similarly, anti-
inflammatory drugs minocycline and inodmethacin
protected from LPS induced injury and attenuated NO
generation. These data implicate the cytotoxicity imposed
by LPS activated microglia, and that this toxicity is likely
mediated by reactive nitrogen and oxygen species.
LPS activated microglia induce endothelial cell death via
NF-B, JAK-STAT and JNK
We further explore the signaling pathways involved in
NO activation in BV2 cells, and that this correlates to
Figure 4 NOS and ROS inhibitors improve microglial viability
and reduce NO accumulation. A panel of NO (AG, 1m M ; LNMA,
1m M ) and ROS (APO, 1m M ; ALO, 50 μM; INDO, 10 μM) inhibitors as
well as minocycline (MINO, 10 μM) known to have anti-inflammatory
properties and NOHA (an arginase inhibitor, 10 μM) were studied in
BV2 cells exposed to LPS (1 μg/ml). BV2 cell viability as assessed by
MTT showed that all of the ROS and NOS inhibitors protected the
cells, but not MINO or NOHA (A). LPS-induced NO in BV2 cells was
attenuated by some (APO, ALO, AG, MINO, LNMA) but not all
inhibitors (B). Neither NOS inhibitor inhibited LPS induced increases
in iNOS (C), shown is a representative blot of at least 3 independent
experiments. (AG: aminoguanidine, a relatively selective iNOS
inhibitor; LNMA: L-NNMA, a non selective NOS inhibitor APO:
apocynin, a NADPH oxidase inhibitor; ALO: allopurinol, a xanthine
oxidase inhibitor; INDO: indomethacin, a COX inhibitor) n = 12
independent observations, *P < 0.0001 versus control; #P < 0.0001
versus LPS.
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Page 7 of 15Figure 5 LPS activates JNK, p38 MAPK, JAK-STAT and NF-Bi nm i c r o g l i a . BV2 cells were treated with LPS, and cell lysates were collected
for Western blot analysis at the various times shown. LPS activated JNK (A, shown using a phospho specific antibody against phosphorylated
JNK, p-JNK), the p38 MAPK ( p-p38) (B) and JAK-STAT, as evidenced by phosphorylated JAK2 ( p-JAK2) (C). NF-B was also activated as shown by
increased phosphorylation of its p65 subunit (D), decreasing levels of its inhibitor protein IB (E) and increased nuclear accumulation of its p65 subunit
(F). Shown are representative blots, plus bar graphs for quantitative comparison using densitometry (A -F). Data are mean ± SEM, n = 3-5
independent experiments. *P < 0.05. Optical densitometric values were normalized to b-actin as a housekeeping control, and are expressed as
percentage of controls.
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Page 8 of 15Figure 6 A: NF-B, JNK and JAK-STAT inhibition prevent LPS- induced iNOS in BV2 cultured alone. BV2 cells were stimulated with LPS in
the presence of inhibitors against MEK1 (PD9805, 20 μM), JNK(SP600125, 10 μM), NF-B (PDTC, 50 μM), JAK-STAT (AG490, 10 μM), p38 MAPK
(SB20580, 10 μM) or PI3K (wortmannin, 100 nM). Inhibition of JNK, NF-B and JAK-STAT reduced NO accumulation, whereas inhibition of MEK1, p38
MAPK and PI3K did not (A). Inhibition of JNK, JAK-STAT and p38 MAPK all protected against LPS-induced toxicity, but inhibition of MEK1, NF-B or PI3K
did not (B).( n=1 2independent observations), *P < 0.05 versus control, #P < 0.05 versus LPS.
Kacimi et al. Journal of Inflammation 2011, 8:7
http://www.journal-inflammation.com/content/8/1/7
Page 9 of 15"
!
#
#4 J
0$ !0/
).$/ -)./
#ONTROL ,03
!'
CTL
LPS
AG+
APO+
INDO+
MINO+
ALO+
LNMA+
0
10
20
30
40
50
60
*
#
#
# #
#
n
i
t
r
i
t
e
,
M
M
CTL
LPS
AG+
APO+
INDO+
MINO+
ALO+
LNMA+
0
25
50
75
100
*
#
#
#
#
#
#
C
e
l
l
 
v
i
a
b
i
l
i
t
y
,
 
%
#
CD33
CD11b
LPS
control
$
control
LPS
Figure 7 Microglia increase endothelial cell death due to LPS, reversal by NOS and ROS inhibitors. While LPS did not affect bEND.3 cells
alone, when cultured with BV2 cells, LPS increased cell death and monolayer disruption of primarily bEND.3 cells (Panel A, LPS) compared to
control cocultures (Panel A, Control). The majority cell type that succumbed to LPS was the bEND.3 rather than BV2 cells. Treatment with
aminoguanidine (Panel A, AG+), apocynin (Panel A, APO+), indomethacin (Panel A, INDO+) or minocycline (Panel A, MINO+) all prevented this
monolayer disruption. To determine which cell type succumbed to LPS exposure, cocultures of bEND.3 and BV2 cells were prepared and
exposed to LPS for 24 h. Immunostains of cell type markers showed that endothelial cells (Panel B, CD33, green) were primarily affected
compared to BV2 cells (CD11b, red), as more BV2 cells remained post LPS treatment than bEND.3 cells. Panels C & D summarize the effect of
various NOS (AG, LNMA), ROS (APO, INDO, ALO) and inflammatory (MINO) inhibitors on LPS-induced cell viability (B) and NO accumulation (C).
CTL: control cultures treated with vehicle, AG: aminoguanidine (1 mM), LNMA: L-NMA (1 mM); APO: apocynin (1 mM), ALO: allopurinol (1 mM);
INDO: indomethacin (50 μM). (n = 4-6 independent observations, *P < 0.05 vs. control, #P < 0.05 versus LPS.
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JNK, JAK-STAT and NF-B inhibition in cocultures
protected cells from LPS while reducing NO accumula-
tion. The extent of NO accumulation in cocultures mir-
rored that seen in BV2 cells alone, with the most robust
effects observed by inhibition of NF-B and JAK-STAT,
but some effect was also observed by JNK inhibition as
well. There was no effect on cell death using inhibitors
of MEK1, PI3K or p38 MAPK.
Discussion
We previously showed that microglia increase injury to
BBB components following experimental stroke and
ischemia-like insults [6]. We now show that microglial
activation by LPS induces injury to endothelial cells, and
this LPS effect requires the presence of microglia. The
mechanism of this effect appears to be mediated
through NF-B, JAK-STAT and JNK, rather than ERK,
p38 MAPK or PI3K. The lack of effect through p38
MAPK is somewhat surprising given prior work empha-
sizing the importance of this pathway in inflammatory
signalling [20,21]. Reasons for this discrepancy are
unclear, but could be due to the model system studied.
Regardless, these observations have therapeutic implica-
tions for a variety of conditions where immune cell
injury to brain endothelial cells contributes to brain
pathology. Since endothelial cell tight junctions make up
the basis of the BBB, damage to these cells would lead
to leakage of brain vessels permitting seepage of poten-
tially toxic serum proteins and blood cells into the brain
tissue. Blood elements are known to exacerbate injury
through vasogenic edema and direct tissue damage [22].
TLR4, the receptor to which LPS binds has been
shown to participate in a variety of central nervous sys-
tem insults not necessarily related to infection [23].
Mice deficient in TLR4 have better outcomes following
experimental stroke and decreased inflammatory
responses [24-29], and the presence of TLR-4 on mono-
cytes in stroke patients correlated to the extent of
ischemic brain injury [30]. This would suggest that
TLR4 signaling plays a significant and detrimental role
in brain ischemia. While its precise ligand has not yet
been identified in non-infectious conditions, a few stu-
dies have implicated heat shock proteins (HSPs), which
may bind TLR4 [31], although these observations could
be explained by contamination of HSP preparations by
LPS or other proteins [32,33]. Regardless, TLR4 signal-
ling is now known to contribute to a variety of non-
infectious brain pathologies.
These studies build on our prior observations that
microglia activated by ischemic stimuli are toxic to consti-
tuents of the blood brain barrier [6]. Here we used micro-
glial BV2 cells stimulated with LPS, as an agonist model
of TLR4 activation. We found that LPS stimulation of
microglia was toxic to endothelial cells, suggesting one
pathway that might explain the toxicity observed in our
ischemia model. As expected, LPS could only stimulate
microglia, but not endothelial cells. LPS also directly
induced cell death in microglia, but not endothelial cells.
However, LPS could only injure endothelial cells when
cocultured with microglia which is not entirely surprising
since endothelial cells are not known to express TLR4
receptors. Nevertheless, this observation underscores the
toxic potential of microglia on these cells. The amount of
cell death in the endothelial cell-microglial cocultures was
mostly due to endothelial cells based on morphological
and immunohistochemical evidence provided here. Micro-
glia suffered a relatively low level of cell death, compared
to endothelial cells. Further, the endothelial monolayer
integrity was markedly disrupted. Thus, LPS induced fac-
tors in the BV2 cells which are cytotoxic. Our data also
suggest that as NO generation is suppressed, BV2 viability
increased in parallel in most cases. The exceptions were
indomethacin which did not suppress NO but did improve
BV2 cell viability, minocycline which reduced both BV2
cell viability and NO generation, and NOHA which had
no effect on either NO or viability.
These data agree with prior studies showing that cyto-
kine activated microglia are toxic to neurons and oligo-
dendrocytes [34,35]. The toxic factors elaborated by
activated microglia appear to include reactive nitrogen
(RNS) and oxygen species (ROS), as pretreatment with
NOS inhibitors (L-NMMA and aminoguanidine) and ROS
inhibitors (apocynin and allopurinol) markedly reduced
endothelial disruption in this in vitro model. Since we also
found that SIN-1 was highly effective in inducing dose
dependent NO accumulation and death, much like that
seen with LPS, we suggest that microglial generation of
RNS and ROS may further lead to the generation of per-
oxynitrite, another highly reactive compound.
To further explore the mechanisms of LPS mediated
injury in our model, we studied several different signal
transduction pathways known to be activated by TLR4
signalling through LPS. Interestingly, we found that sev-
eral downstream kinase and transcription factors (JNK,
p38 MAPK, JAK-STAT and NF-B) were activated.
These factors could then lead to upregulation of immune
molecules including iNOS and NADPH oxidase (NOX)
which then generate NO and superoxide, respectively.
These factors singly, as well as peroxynitrite, generated
from NO and superoxide, are known to be cytotoxic
(Figure 9). Interestingly, activated p38 MAPK did not
appear to participate in cell survival or NO generation.
LPS induced marked nuclear translocation of NF-Bi n
microglia and its inhibition by PDTC suppressed NO
generation, but did not improve BV2 cell viability. Our
data indicate that while multiple transcription factor
pathways are upregulated by LPS, NF-B and JAK-STAT
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Figure 8 NF-B, JAK-STAT and JNK kinase inhibition prevent LPS- induced iNOS and protect from LPS -induced injury in BV2 and
bEND.3 coculture model. Panel A: LPS treatment of bEND.3/BV2 cocultures (LPS) increased cell death and disruption of bEND.3 monolayers
compared to control cocultures (Control). Treatment with inhibitors to block JNK (SP600125), JAK-STAT (AG490) or NF-B (PDTC) reduced this
disruption, whereas treatment with a MEK1 inhibitor (PD98059) did not. Panels B & C summarize the effect of these various inhibitors on LPS-
induced cell viability (B) and NO accumulation (C). These data show that inhibition of JNK, JAK-STAT and NF-B improve cell viability while
decreasing NO accumulation, whereas inhibition of MEK1, p38 MAPK (SB 203580) and PI3K (wortmannin) do not. CTL: control cultures treated
with vehicle. (n = 12 independent observations), *P < 0.05vs. control, # P < 0.05 versus LPS).
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cells, as well as JNK to a lesser extent. The differential
effects of NF-B versus JAK-STAT and JNK inhibition on
cytoprotection also indicate that inhibition of microglial
activation does not always correlate to their viability.
However, when cultured with endothelial cells, NF-B
inhibition improved overall coculture viability and
decreased NO. Thus, NF-B may be essential for micro-
glial viability while also suppressing its activation. Since
microglia are essential to other aspects of tissue viability
such as protecting against microbial invasion and assist
in recovery and repair [36,37], a therapeutic intervention
that suppresses microglial cytotoxicity while preventing
microglial death may be more desirable.
JAK-STAT signaling promotes and modulates inflamma-
tory processes. Phosphorylated JAKs lead to the activation
of several substrates and provides docking sites for STATs,
which in turn become phosphorylated for full STAT
activity. Phosphorylated STATs are released from the
receptor complex and form dimers which translocate to
the nucleus. Once in the nucleus, they directly bind to the
promoter region of specific target genes, many of which
are involved in immune responses [38,39]. When we inhib-
ited JAK-STAT in our model, not only did we observe
decreased NO generation, but we also observed improved
microglial viability. JAK-STAT inhibition also improved
overall viability in the cocultures. Thus, JAK-STAT may be
a preferred therapeutic target, as its inhibition appears to
inhibit immune responses but does not destroy microglia
while doing so.
MAPKs are important mediators involved in a variety of
cell signalling functions, including inflammation [40]. The
MAPK family includes p38, ERK and JNK, of which p38
and JNK are activated in response to environmental stress,
whereas ERK is involved in growth responses. However,
we did not observe any significant effect in our model by
LPS
TLR4
MAPKs
JNK p38
NF-NB
JAK-STAT
iNOS, NOX
NO
Cell death
AG490
SP600125 SB203580
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Figure 9 Proposed mechanism of LPS signaling in microglia leading to endothelial, and microglial cell death. LPS binds toll-like receptor 4
(TLR4) on the surface of microglia leading to signaling in several pathways., NF-B, the MAPKs and JAK-STAT. MAPKs then activate JNK (JNK kinase)
and the p38 MAPK (p38). NF-B, JAK-STAT and to a lesser extent, JNK lead to upregulation of immune factors iNOS and NADPH oxidase (NOX). These
factors lead to the production of nitric oxide (NO) and superoxide (O2-), respectively. These molecules are themselves known to be directly cytoxic, but
may also combine to form peroxynitrite (ONOO-) which can also kill cells. Also indicated in the figure are the NF-B, p38 MAPK, JAK-STAT and JNK
inhibitors studied. (PDTC = pyrrolidinecarbodithoic acid).
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effect when blocking JNK. PI3K inhibition did not affect
NO accumulation or cell death in our models, suggesting
that it may not be an important downstream TLR4 target
in cytoprotection.
We show that LPS activated microglia are toxic to
endothelial cells, and in particular, targeting the JAK-
STAT pathway in microglia would confer protection of
both endothelial cells and microglia, and prevent micro-
glial activation. This may be in preference to targeting
NF-B which appears to be toxic to microglia, and JNK,
where protection was less robust. Thus, JAK-STAT inhi-
bition to prevent microglial toxicity would have implica-
tions for preserving the BBB in relevant disease states
such as sepsis and even non-infectious brain pathologies
such as ischemia and trauma.
Conclusions
LPS activated microglia are toxic to endothelial cells,
and the pathways mediating this effect appear to involve
NF-B, JAK-STAT and JNK, rather than ERK, p38
MAPK or PI3K. Targeting the former pathways in
microglia, especially JAK-STAT may be useful in pre-
venting BBB disruption.
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